Effect of S-1 maintenance chemotherapy following DCF regimen in patients with advanced gastric cancer
10.3969/j.issn.1673-4254.2014.07.29
- VernacularTitle:DCF方案一线化疗后替吉奥维持治疗晚期胃癌
- Author:
Jinghua CHEN
1
;
Weixi SHEN
;
Junxian XIA
;
Ruilian XU
;
Meiqin ZHU
;
Min XU
Author Information
1. 暨南大学第二临床医学院/深圳市人民医院肿瘤内科
- Keywords:
advanced gastric cancer;
S-1;
maintenance chemotherapy
- From:
Journal of Southern Medical University
2014;(7):1057-1060
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and adverse effect of DCF regimen with subsequent S-1 maintenance chemotherapy in patients with advanced gastric cancer (AGC). Methods Sixty AGC patients without disease progression after 4 to 6 cycles of DCF regimen as the first-line chemotherapy were randomized into maintenance group and control group (30 patients each). The patients in the maintenance group received maintenance chemotherapy with S-1 (40 mg/m2, twice daily for 14 days; 21 days for a treatment cycle) until disease progression or with intolerant toxicity, and those in the control group received optimal supportive care. Results The response rate (CR+PR) was 33.3%in the maintenance group, significantly higher than that in the control group (3.33%, P<0.05), and the disease control rate (CR+PR+SD) also differed significantly between the two groups (73.3% vs 46.7%, P<0.05). The median time to progression was 7.9 months in the maintenance group and 6.8 months in the control group, with median overall survival time of 13.8 and 11.7 months, respectively (P>0.05). The most common adverse effect in the maintenance group included nausea, vomiting, leucocytopenia, and hand-foot syndrome; no death occurred in relation to the therapy. Conclusions S-1 maintenance chemotherapy, with a tolerable toxicity profile, can improve the RR, DCR and median time to progression in AGC patients who respond to DCF regimen, but its efficacy still awaits further evaluation.
